文献速递慢性肾脏病

阿哌沙班与华法林对CKD进展影响的比较

CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
PubMed 文献 · Am J Kidney Dis · 2021-01-06

本研究为回顾性队列研究,纳入2013至2017年间接受阿哌沙班或华法林新处方的Medicare受益人(CKD 3-5期且新发房颤),共12816人。意向性分析显示阿哌沙班与华法林相比,CKD分期进展风险较低(HR 0.90,95%CI 0.82-0.99),但新发肾衰竭风险无显著差异(HR 0.98,95%CI 0.79-1.22)。

要点

  • 阿哌沙班较华法林与CKD分期进展风险降低相关(HR 0.90)。
  • 阿哌沙班与新发肾衰竭风险无显著关联(HR 0.98)。
  • CKD定义基于诊断代码,结果可能不适用于非Medicare人群。

核心结论

  • 阿哌沙班较华法林与CKD分期进展风险降低相关,但未降低新发肾衰竭风险。

研究设计与样本

  • 回顾性队列研究,纳入12816例Medicare受益人(CKD 3-5期且新发房颤),2013至2017年接受阿哌沙班或华法林新处方。

主要发现

  • 意向性分析中,阿哌沙班较华法林的新发肾衰竭HR为0.98(95%CI 0.79-1.22),CKD分期进展HR为0.90(95%CI 0.82-0.99)。
  • 药物转换截尾分析中,对应HR分别为0.81(95%CI 0.56-1.17)和0.81(95%CI 0.70-0.92)。
  • 亚组和敏感性分析结果相似。

临床怎么用

  • 对于合并房颤的CKD 3-5期患者,阿哌沙班可能延缓CKD分期进展,但预防新发肾衰竭的证据不足。

局限性

  • CKD基于索赔诊断代码定义,结果可能不适用于非Medicare的CKD人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Comparing kidney disease progression among patients treated with direct oral anticoagulants (DOACs) versus warfarin has not been well studied. We hypothesized that apixaban would be associated with lower risks of progression of chronic kidney disease (CKD) and progression to incident kidney failure than warfarin in patients with atrial fibrillation (AF). STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Medicare recipients with stage 3, 4, or 5 CKD and incident AF who received a new prescription for apixaban or warfarin from 2013 through 2017. EXPOSURE: Apixaban or warfarin. OUTCOMES: Progression to incident kidney failure or, separately, to a more advanced stage of CKD. ANALYTICAL APPROACH: Marginal structural cause-specific proportional hazards models with inverse probability weighting to estimate marginal hazard ratios (HRs) for each outcome. HRs compared apixaban to warfarin in intention-to-treat and censored-at-drug-switch analyses. RESULTS: 12,816 individuals met inclusion criteria (50.3% received apixaban; 49.7% received warfarin). After weighting, the mean age of the cohort was 80 ± 7 years, 51% were women, and 88% were White. Approximately 84% had stage 3, 15% had stage 4, and 1% had stage 5 CKD. In the intention-to-treat analysis, apixaban, relative to warfarin, was associated with an HR of developing incident kidney failure of 0.98 (95% confidence interval [CI], 0.79-1.22) and of CKD stage progression of 0.90 (95% CI, 0.82-0.99). Corresponding HRs for censored-at-drug-switch analyses were 0.81 (95% CI, 0.56-1.17) and 0.81 (95% CI, 0.70-0.92). Results were similar for a series of subgroup and sensitivity analyses. LIMITATIONS: CKD was defined based on diagnosis codes from claims; findings may not be generalizable to non-Medicare CKD populations. CONCLUSIONS: Apixaban, compared with warfarin, was associated with lower risk of CKD stage progression, but not with incident kidney failure.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Wetmore JB, Yan H, Herzog CA, et al. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. Am J Kidney Dis. 2021. PMID: 33421454. doi:10.1053/j.ajkd.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。